Epic Mitral

Designed to be
Versatile, Made to
be Adaptable

MITIGATING REGURGITATION

The Epic Mitral stented tissue valve with Linx anticalcification (AC) technology achieves minimal valvular regurgitation by providing two features crucial in the mitral position: impressive paravalvular cuff sealing and central leaflet coaptation.

Epic Mitral also features the FlexFit system, which helps facilitate the implant process.

The FlexFit system includes:

  • Ratcheting system that allows reduction of valve profile
  • Flexible polymer stent that can be ratcheted for lower profile and facilitates lower tissue stress during normal valve function
  • Click-in holder that allows the holder to be removed while maintaining the lower ratcheted valve profile
  • Flexible valve sizers
  • 2 x 10 second valve rinse time

The valve’s triple composite design uses three separate porcine leaflets to optimize leaflet coaptation, reduce stress, and mitigate regurgitation. The conformable sewing cuff further minimizes regurgitation in high-risk anatomies, such as a calcified mitral annulus.

  • SOFT SEWING CUFF

    Provides limited suture drag and parachuting forces

  • SYMMETRICAL TRIPLE COMPOSITE DESIGN

    Eliminates Septal muscle bar leaflet and the need for orientation which optimizes leaflet coaptation and reduces leaflet stress

  • UNIQUE PERICARDIAL SHIELD

    Provides a tissue-to-tissue interface to help prevent the risk of abrasion

  • Flexible Polymer Stent

    Reduces valve overall profile for better maneuverability during implantation

  • Ratcheting Holder

    Mitigates the potential for suture looping

Epic Mitral Valve for Streamlined, Customized Implantation

The Epic Mitral valve has been designed not only for easy implantability, but to allow surgeons to customize their implant techniques based upon patient needs—which can minimize implant-related complications.

Epic Mitral ValvevsMagna Mitral Ease Valve
Lowest overall ventricular protrusion in all
valve sizes, with all 3 stent posts the same height1
ProfileAsymmetrical design results in the posterior
strut protruding farther into the ventricle than Epic in all sizes2
Designed with a flexible polyester cuff1 that
provides limited suture drag and needle
penetration forces
CuffRigid silicone sewing ring is covered by
polytetrafluoroethylene (PTFE) cloth2
Symmetrical valve design provides flexibility in
valve placement during implantation
ShapeAsymmetrical sewing band
is designed for a specific orientation2
Valve sizes, which are based on the
measurement of the tissue annulus,1 ensure
accurate sizing
SizingValve sizes are based on the measurement of the stent diameter2
Polymer stent deflects when ratcheted, aiding
implantability during minimally invasive
surgery and reducing the risk of suture looping
StentDesigned with a metallic stent; physicians
must exercise care to prevent folding or
deformation of the stent2
Ergonomic FlexFit system is a simple 2-step
click-in and click-off process
HolderTricentrix is a 7-step implantation process3

Anticalcification Advantages

Abbott’s unique Linx AC technology—to promote anticalcification* —is designed to improve long-term performance and valve durability. The Linx AC treatment has demonstrated resistance to calcification by:

  • Extracting lipids4
  • Reducing free aldehydes5,6
  • Minimizing cholesterol uptake7
  • Stabilizing leaflet collagen7

*No clinical data currently available have evaluated the long-term impact of anticalcification tissue treatment in humans

    AP2947047-WBO Rev. A

    References
    1. Epic Valve IFU.
    2. Magna Mitral Ease IFU.
    3. Magna Mitral Ease Heart Valve Implantation Guide. www.edwards.com/eu/products/heartvalves/Pages/mmeguideppt.aspx. Accessed August 23, 2018.
    4. Vyavahare, N, Hirsch, D, Lerner, E, et al. Prevention of bioprosthetic heart valve calcification by ethanol preincubation. Circulation. 1997:95;479-488. doi.org/10.1161/01.CIR.95.2.479.
    5. Kelly SJ, Ogle MF, Carlyle WC, et al. Biocompatibility and calcification of bioprosthetic heart valves. Presented at: Society for Biomaterials, Sixth World Biomaterials Congress Transaction. May 2000:1353.
    6. Frater RWM, Seifter E, Liao K, et al. Chapter 8. In: Gabbay, S, Wheatley DJ, eds. Advances in Anticalcific and Antidegenerative Treatment of Heart Valve Bioprostheses. 1st ed. Austin: Silent Partners, Inc; 1997:105-113.
    7. Vyavahare NR, Hirsch D, Lerner E, et al. Prevention of calcification of glutaraldehyde-crosslinked porcine aortic cusps by ethanol preincubation: mechanistic studies of protein structure and water-biomaterial relationships. J Biomed Mater Res. 1998;40:577-585.
       

    This site uses cookies to improve your experience.

    To find out more please read our Privacy and Cookies policy.

    Ok

    YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

    Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.